肺炎球菌ワクチン市場：ワクチンタイプ別、対象集団別、投与経路別、流通チャネル別、地域別

肺炎球菌ワクチンの世界市場は、2025年には93億8,000万米ドルと推定され、2032年には132億9,000万米ドルに達すると予測され、2025年から2032年にかけてCAGR5.1％で成長すると予測されます。

図.肺炎球菌ワクチン市場シェア（%）、2025年地域別

肺炎球菌ワクチンの世界市場成長は、世界の肺炎球菌疾患の罹患率の上昇や各国政府による予防接種プログラムの増加といった要因によって牽引されています。さらに、肺炎球菌ワクチン接種に関する人々の意識の高まりも市場成長の原動力となっています。しかし、肺炎球菌ワクチンの開発と生産に関連する高コストが市場成長の妨げとなる可能性があります。手頃な価格で効果的なワクチンを開発するための継続的な研究活動は、近い将来に新たな機会を提供する可能性があります。

市場力学：

肺炎球菌ワクチンの世界市場成長は、主に肺炎球菌による肺炎、髄膜炎、その他の重篤な感染症の世界の有病率の上昇に牽引されています。世界保健機関（WHO）によると、肺炎は5歳未満の子供の死亡原因の上位5つのうちの1つです。さらに、国の予防接種スケジュールを通じて予防接種プログラムを推進するための政府資金やイニシアチブの増加は、市場の成長を促進する可能性があります。しかし、肺炎球菌ワクチンの研究開発・製造コストが高いことが市場拡大の妨げになる可能性があります。新しい多価肺炎球菌製剤の安全性と有効性を評価する臨床試験が進行中であることが、市場の成長を促進する可能性があります。新興国はヘルスケアインフラが整備されているため、市場参入者にとって大きなチャンスとなります。

本調査の主な特徴

本レポートでは、世界の肺炎球菌ワクチン市場を詳細に分析し、2024年を基準年とした予測期間（2025年～2032年）の市場規模（10億米ドル）と年間平均成長率（CAGR%）を掲載しています。

また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案のマトリックスについて説明しています。

また市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する主要考察も提供しています。

世界の肺炎球菌ワクチン市場における主要企業プロファイルを、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいて掲載しています。

主な企業は、ファイザー、メルク、GSK、サノフィなどです。

本レポートの洞察により、マーケティング担当者や各企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関して、十分な情報に基づいた意思決定を行うことができます。

肺炎球菌ワクチンの世界市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー

第3章 市場力学、規制、動向分析

• 市場力学
• 影響分析
• 主なハイライト
• 規制シナリオ
• 製品の発売/承認
• PEST分析
• PORTERの分析
• 合併と買収のシナリオ

第4章 世界の肺炎球菌ワクチン市場、ワクチンタイプ別、2020年～2032年（10億米ドル）

• 肺炎球菌結合ワクチン（PCV）
• 肺炎球菌多糖体ワクチン（PPV）

第5章 世界の肺炎球菌ワクチン市場、対象集団別、2020年-2032年、（10億米ドル）

• 成人（65歳以上）
• 小児（5歳未満）
• 高リスク成人（18～64歳）

第6章 世界の肺炎球菌ワクチン市場、投与経路別、2020年～2032年、（10億米ドル）

• 筋肉内
• 皮下

第7章 世界の肺炎球菌ワクチン市場、流通チャネル別、2020年～2032年（10億米ドル）

• 病院薬局
• 小売薬局
• オンライン薬局

第8章 世界の肺炎球菌ワクチン市場、地域別、2020年-2032年、（10億米ドル）

• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第9章 競合情勢

• Pfizer Inc.
• Merck & Co., Inc.
• GlaxoSmithKline plc（GSK）
• Sanofi
• CSL Limited
• Serum Institute of India Pvt. Ltd.
• Vaxcyte, Inc.
• Astellas Pharma Inc.
• Panacea Biotec Ltd.
• Walvax Biotechnology Co., Ltd.
• Beijing Minhai Biotechnology Co., Ltd.
• Merck KGaA
• Takeda Pharmaceutical Company Limited
• AbbVie Inc.
• Novartis AG
• Johnson & Johnson
• Biovac
• Bharat Biotech
• Inovio Pharmaceuticals, Inc.
• Hilleman Laboratories Pvt. Ltd

第10章 アナリストの推奨事項

第11章 参考文献と調査手法

• 参考文献
• 調査手法
• 出版社について

Global Pneumococcal Vaccines Market is estimated to be valued at USD 9.38 Bn in 2025 and is expected to reach USD 13.29 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.

Figure. Pneumococcal Vaccines Market Share (%), By Region 2025

Global pneumococcal vaccines market growth is driven by factors such as rising incidence of pneumococcal diseases worldwide and growing immunization programs by various governments. Moreover, increasing awareness among people regarding pneumococcal vaccination can also drive the market growth. However, high costs associated with pneumococcal vaccines development and production can hamper the market growth. Ongoing research activities for developing affordable and effective vaccines can offer new opportunities in the near future.

Market Dynamics:

Global pneumococcal vaccines market growth is primarily driven by rising prevalence of pneumococcal pneumonia, meningitis, and other serious infections caused by Streptococcus pneumoniae bacteria worldwide. As per the World Health Organization (WHO), pneumonia is one of the top five causes of death in children under age of 5 years. Moreover, increasing government funding and initiatives to promote immunization programs through national immunization schedules can drive the market growth. However, high research, development and production costs of pneumococcal vaccines can hamper the market expansion. Ongoing clinical trials assessing the safety and efficacy of new multivalent pneumococcal formulations can drive the market growth. Emerging economies present significant opportunities for market players owing to improving healthcare infrastructures in these countries.

Key features of the study:

This report provides in-depth analysis of the global pneumococcal vaccines market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global pneumococcal vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., Merck & Co., GSK plc., and Sanofi

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global pneumococcal vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Detailed Segmentation-

• By Vaccine Type
  • Pneumococcal Conjugate Vaccines (PCVs)
  • PCV13 (Prevnar 13/Prevenar 13)
  • PCV10 (Synflorix)
  • PCV7 (Prevnar/Prevenar)
  • Pneumococcal Polysaccharide Vaccines (PPVs)
  • PPSV23 (Pneumovax 23)
  • PPSV14 (Pneumo 14)
• By Target Population
  • Adults (>= 65 years)
  • Children (< 5 years)
  • High-Risk Adults (18-64 years)
• By Route of Administration
  • Intramuscular
  • Subcutaneous
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
• Key Players Insights
  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc (GSK)
  • Sanofi
  • CSL Limited
  • Serum Institute of India Pvt. Ltd.
  • Vaxcyte, Inc.
  • Astellas Pharma Inc.
  • Panacea Biotec Ltd.
  • Walvax Biotechnology Co., Ltd.
  • Beijing Minhai Biotechnology Co., Ltd.
  • Merck KGaA
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
  • Novartis AG
  • Johnson & Johnson
  • Biovac
  • Bharat Biotech
  • Inovio Pharmaceuticals, Inc.
  • Hilleman Laboratories Pvt. Ltd

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Pneumococcal Vaccines Market, By Vaccine Type
  • Global Pneumococcal Vaccines Market, By Target Population
  • Global Pneumococcal Vaccines Market, By Route of Administration
  • Global Pneumococcal Vaccines Market, By Distribution Channel
  • Global Pneumococcal Vaccines Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Pneumococcal Vaccines Market, By Vaccine Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Pneumococcal Conjugate Vaccines (PCVs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • PCV13 (Prevnar 13/Prevenar 13)
  • PCV10 (Synflorix)
  • PCV7 (Prevnar/Prevenar)
• Pneumococcal Polysaccharide Vaccines (PPVs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • PPSV23 (Pneumovax 23)
  • PPSV14 (Pneumo 14)

5. Global Pneumococcal Vaccines Market, By Target Population, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Adults (>= 65 years)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Children (< 5 years)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• High-Risk Adults (18-64 years)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Pneumococcal Vaccines Market, By Route of Administration, 2020-2032, (USD Bn)

• Intramuscular
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Subcutaneous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Pneumococcal Vaccines Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Pneumococcal Vaccines Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021- 2032, (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country/Sub-region, 2020 - 2032, (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline plc (GSK)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• CSL Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Serum Institute of India Pvt. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Vaxcyte, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Astellas Pharma Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Panacea Biotec Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Walvax Biotechnology Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Beijing Minhai Biotechnology Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck KGaA
• Takeda Pharmaceutical Company Limited
• AbbVie Inc.
• Novartis AG
• Johnson & Johnson
• Biovac
• Bharat Biotech
• Inovio Pharmaceuticals, Inc.
• Hilleman Laboratories Pvt. Ltd

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us